TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Weinberger, Edwards Back Away From Fight Over NCI’s Independence, Ask For Authorization Figures To Be Dropped February 8, 1974
TCL Archive Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years May 9, 2014
